Amaxa Overview

  • Founded
  • 1998
  • Status
  • Acquired/​Merged
  • Employees
  • 160
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $148M
Latest Deal Amount

Amaxa General Information


Developer of a Nucleofector device that that is designed to transfer genes for primary cell research where non-viral gene transfer is required.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • Nattermannallee 1
  • 50829 Cologne
  • Germany
+49 0221 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amaxa Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 02-Jul-2008 $148M 000.00 00000 Completed Product Development
2. Early Stage VC 13-Jun-2001 000.00 000.00 Completed Product Development
1. Early Stage VC Completed
To view Amaxa’s complete valuation and funding history, request access »

Amaxa Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amaxa Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Earlybird Venture Capital Venture Capital Minority 000 0000 000000 0
NRW.Bank Investment Bank Minority 000 0000 000000 0
Technologie-Beteiligungs-Gesellschaft Venture Capital Minority 000 0000 000000 0
Technomedia Kapitalbeteiligungsgesellschaft Koeln Venture Capital Minority 000 0000 000000 0
To view Amaxa’s complete investors history, request access »